Introduction Given the success of paediatric transplantation, there is now a growing population of patients that undergo transition from paediatric to adult healthcare services. In the renal transplant setting, these patients appear to be at increased risk of short-term graft loss.
1 However, the outcome of liver transplant patients who undergo transition remains unclear. Our aim was, therefore, to examine the patient and graft survival of liver transplant patients who undergo paediatric to adult healthcare transition. Methods Single-centre retrospective study of 85 liver transplant recipients who underwent transition from paediatric to adult healthcare services between March 2001 and August 2011 (median follow-up time from transition 4.1 (range 0.2e10.7) years). Results During the 10-year period, there were 48 (56.5%) males and 37 (43.5%) females. The median age at time of transplant was 8.4 (range 0.6e17.9) years. The initial indications for transplantation were: biliary atresia (27.1%), Wilson's (14.1%), other acute liver failure (11.8%), cystic fibrosis (9.4%), autoimmune hepatitis (8.2%), cryptogenic cirrhosis (4.7%), oxalosis (4.7%), other (20.0%). At the time of transition, the median age of the patients was 18.9 (range 16.6e23.1) years. 84.7% of patients were on their first graft, 12.9% were on their second and 2.4% were on their third at this point. The immunosuppression at transition was calcineurin inhibitor (CNI) monotherapy in 38.2%, a CNI combination regimen in 20.6%, and a CNI free regimen in 41.2%. Following transition, the estimated 1-, 5-and 10-year patient survival was 98.6%, 96.8% and 91.4%, respectively, and the estimated 1-, 5-and 10-year graft survival was 98.6%, 95.0% and 89.4%. Conclusion Our results demonstrate that paediatric liver transplant recipients have a better outcome than previously reported in renal transplant recipients after transition.
1 This may suggest that this group of patients are more tolerant of their graft or that transition was adequately managed. Introduction Liver Transplantation (LT) is a well-recognised treatment option for selected patients with hepatocellular carcinoma (HCC). However there is always concern regarding tumour progression while on the waiting list. As yet there is no agreed consensus on how to reduce progression of disease while waiting. UK guidelines recommend local ablative therapy for all HCC patients being considered for LT. We have sought to review this practice and evaluate its benefit.
Methods All consecutive patients with HCC who have undergone LT between 2001 and 2010 were identified from our prospectively maintained database. All patients are discussed at our LT assessment meeting and also at a separate HPB MDT for consideration of bridging treatment. Our imaging protocol includes (1) triple phase CT to assess the number of hyper vascular liver lesions, presence of venous washout, or extra-hepatic disease, (2) MRI to re-characterise any atypical lesions or (3) CEUS for further characterisation.
Patients undergo either trans-arterial chemo-embolisation (TACE) and/or percutaneous/laparoscopic radio frequency ablation (RFA) while on the LT waiting list. The response to bridging treatment is assessed and intensive surveillance for disease progression is also undertaken.
Results 55 HCC patients underwent LT (M:F¼43:12), Childs-Pugh A (n¼9), B (n¼ 30) and C (n¼16). Bridging treatments were either TACE n¼31, RFA n¼28, or both treatments n¼4. TACE treatments per patient were 1 (n¼12), 2 (n¼12), 3 (n¼6) or 4 (n¼1). Six patients did not undergo any form of bridging treatment as they rapidly progressed to LT. The response to bridging treatment was complete (n¼8), good (n¼28), poor (n¼4) or no response (n¼15). There were two deaths within 100 post-operative days. At last follow-up, 28 patients had died due to recurrent disease, stable recurrent disease n¼4 or disease free n¼ 21. Overall survival [median (95% CI)] was 62 (53e71) months. For those with a good response to bridging treatments it was 67 (55e79) months while for those with poor/no response it was 53 (42e64) months (log-rank p¼0.059). Conclusion This study demonstrates the feasibility of various bridging treatments for patients with HCC who await liver transplantation in the UK. In combination with careful patient selection and surveillance acceptable rates of survival can be achieved.
